Dana F. DeSantis
Dana F. DeSantis has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Chithra Sangli
Tempus AI, Inc Chicago Illinois USA
18 shared publications - Christine Lo
Tempus AI, Inc., 3 Chicago, Illinois, USA
18 shared publications - Daniel Neems
Tempus AI, Inc., 3 Chicago, Illinois, USA
18 shared publications - Farahnaz Islam
Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA
18 shared publications - Hala Boulos
Tempus AI, Inc., 3 Chicago, Illinois, USA
18 shared publications - Halla Nimeiri
Tempus AI, Inc., Chicago, Illinois
18 shared publications
Latest Publications
- Open Access
Multimodal Immune Profile Score (IPS) as a Pan-Cancer Biomarker for Stratifying Outcomes of Immune Checkpoint Inhibitor Benefit in Microsatellite Stable Colorectal Cancer and Rare Solid Tumors
Background: Immune checkpoint inhibitor (ICI) therapies have revolutionized oncology, but identifying patients who benefit remains a challenge, particularly in populations where ICIs are not the standard of care, including microsatellite stable colorectal cancer (MSS CRC) and rare solid cancers. We evaluated real-world performance of the Immune Profile Score (IPS), a validated DNA- and RNA-based molecular signature, in these cohorts. Methods: In an exploratory analysis, we analyzed two real-world cohorts: 1) MSS CRC; and 2) MSS, tumor mutational burden-low rare solid cancers treated with off-label ICI. IPS-High and IPS-Low were calculated using a previously validated threshold. Cox proportional hazards models were fit to demonstrate prognostic utility for real-world overall survival (rwOS). In MSS CRC, time-to-next-treatment (TTNT) on prior non-ICI therapy was compared to rwOS on subsequent ICI therapy. Results: In MSS CRC (n=46), IPS-High patients (13%) demonstrated clinically meaningful improvement in rwOS versus IPS-Low (Median OS: not reached vs 7.3 months; HR = 0.22, 90% CI 0.04-1.16). While IPS was not associated with TTNT on the preceding non-ICI line (HR = 1.07, 90% CI 0.60-1.91), it was associated with OS in patients receiving later line ICI (HR 0.21, 90% CI 0.04-1.22). In the rare cancers cohort (n=90; 26 unique malignancies), IPS-High (17.8%) was associated with longer OS to ICI therapy (HR = 0.26, 90% CI 0.11-0.61), even when restricted to histologies represented in both IPS groups (HR = 0.18, 90%, CI 0.05-0.62). Conclusions: Preliminary evidence suggests that IPS may serve as a generalizable, pan-cancer biomarker capable of stratifying outcomes for ICI treatment in populations traditionally excluded from immunotherapy benefit.
Open AccessMultimodal Immune Profile Score (IPS) as a Pan-Cancer Biomarker for Stratifying Outcomes of Immune Checkpoint Inhibitor Benefit in Microsatellite Stable Colorectal Cancer and Rare Solid Tumors
Background: Immune checkpoint inhibitor (ICI) therapies have revolutionized oncology, but identifying patients who benefit remains a challenge, particularly in populations where ICIs are not the standard of care, including microsatellite stable colorectal cancer (MSS CRC) and rare solid cancers. We evaluated real-world performance of the Immune Profile Score (IPS), a validated DNA- and RNA-based molecular signature, in these cohorts. Methods: In an exploratory analysis, we analyzed two real-world cohorts: 1) MSS CRC; and 2) MSS, tumor mutational burden-low rare solid cancers treated with off-label ICI. IPS-High and IPS-Low were calculated using a previously validated threshold. Cox proportional hazards models were fit to demonstrate prognostic utility for real-world overall survival (rwOS). In MSS CRC, time-to-next-treatment (TTNT) on prior non-ICI therapy was compared to rwOS on subsequent ICI therapy. Results: In MSS CRC (n=46), IPS-High patients (13%) demonstrated clinically meaningful improvement in rwOS versus IPS-Low (Median OS: not reached vs 7.3 months; HR = 0.22, 90% CI 0.04-1.16). While IPS was not associated with TTNT on the preceding non-ICI line (HR = 1.07, 90% CI 0.60-1.91), it was associated with OS in patients receiving later line ICI (HR 0.21, 90% CI 0.04-1.22). In the rare cancers cohort (n=90; 26 unique malignancies), IPS-High (17.8%) was associated with longer OS to ICI therapy (HR = 0.26, 90% CI 0.11-0.61), even when restricted to histologies represented in both IPS groups (HR = 0.18, 90%, CI 0.05-0.62). Conclusions: Preliminary evidence suggests that IPS may serve as a generalizable, pan-cancer biomarker capable of stratifying outcomes for ICI treatment in populations traditionally excluded from immunotherapy benefit.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S3 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S3 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S1 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S1 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Purpose:Resection of liver metastases improves survival in patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD), but relapse remains common. Postresection circulating tumor DNA (ctDNA) is a valid prognostic biomarker; however, no data are available regarding the prognostic effect of presurgery ctDNA after upfront chemotherapy.Experimental Design:Patients (N = 116) with initially unresectable mCRC with LLD who underwent resection after upfront chemotherapy were included. Patients were sequenced with a tumor-naïve ctDNA-based minimal residual disease (MRD) assay at baseline (before chemotherapy), before surgery, and after surgery.Results:Presurgery ctDNA status was not significantly associated with relapse-free survival (RFS). However, exploratory analyses demonstrated that a ≥50% reduction in variant allele frequency from baseline to before surgery was independently associated with improved RFS (median RFS: 21.0 vs. 9.8 months; HR: 2.19; P = 0.014), aligned with multivariate analysis (P = 0.022). Postsurgery ctDNA positivity was strongly predictive of recurrence (HR: 6.66; P < 0.001), with 100% specificity and 56.4% sensitivity. ctDNA dynamics from before to after surgery further stratified recurrence risk, regardless of adjuvant chemotherapy status. ctDNA dynamics from before to after surgery further stratified recurrence risk. Quantitative ctDNA measures (predicted tumor fragments per million) also correlated with RFS.Conclusions:Use of a tumor-naïve MRD assay increased the accuracy of detecting ctDNA after chemotherapy treatment, when a significant drop of ctDNA amount is expected compared with tests routinely used in metastatic disease. Presurgery ctDNA dynamics were prognostic with respect to RFS and may help stratify patients’ prognosis prior to resection, potentially informing personalized treatment decisions.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Purpose:Resection of liver metastases improves survival in patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD), but relapse remains common. Postresection circulating tumor DNA (ctDNA) is a valid prognostic biomarker; however, no data are available regarding the prognostic effect of presurgery ctDNA after upfront chemotherapy.Experimental Design:Patients (N = 116) with initially unresectable mCRC with LLD who underwent resection after upfront chemotherapy were included. Patients were sequenced with a tumor-naïve ctDNA-based minimal residual disease (MRD) assay at baseline (before chemotherapy), before surgery, and after surgery.Results:Presurgery ctDNA status was not significantly associated with relapse-free survival (RFS). However, exploratory analyses demonstrated that a ≥50% reduction in variant allele frequency from baseline to before surgery was independently associated with improved RFS (median RFS: 21.0 vs. 9.8 months; HR: 2.19; P = 0.014), aligned with multivariate analysis (P = 0.022). Postsurgery ctDNA positivity was strongly predictive of recurrence (HR: 6.66; P < 0.001), with 100% specificity and 56.4% sensitivity. ctDNA dynamics from before to after surgery further stratified recurrence risk, regardless of adjuvant chemotherapy status. ctDNA dynamics from before to after surgery further stratified recurrence risk. Quantitative ctDNA measures (predicted tumor fragments per million) also correlated with RFS.Conclusions:Use of a tumor-naïve MRD assay increased the accuracy of detecting ctDNA after chemotherapy treatment, when a significant drop of ctDNA amount is expected compared with tests routinely used in metastatic disease. Presurgery ctDNA dynamics were prognostic with respect to RFS and may help stratify patients’ prognosis prior to resection, potentially informing personalized treatment decisions.